Leading From the Front: Precision, Practice, and the Pharmacist's Role

The final day of the Oncology Pharmacists Connect 2026 covered ground as diverse as the disease states it explored, moving through cutaneous oncology, supportive care, precision medicine, and thoracic malignancies—each session reinforcing a theme that ran throughout the meeting: the pharmacist's role in oncology is no longer confined to dispensing and monitoring. It extends into molecular interpretation, care coordination, patient navigation, and the kind of proactive clinical infrastructure that determines whether a trial advance becomes a real-world outcome.

Breakthroughs in Cutaneous Oncology

The landscape for treatment of cutaneous malignancies has shifted considerably in recent years, and the panelists highlighted a key development: personalized vaccines. The 5-year readout from KEYNOTE-942 showed that patients treated with intismeran autogene (Moderna), a personalized mRNA neoantigen vaccine, were recurrence-free and distant metastasis-free survival remained meaningfully higher in the combination arm compared to pembrolizumab alone, with hazard ratios favoring the vaccine across both end points. The immunologic rationale—that intisomeran activates tumor-specific T-cell clonotypes that pembrolizumab alone cannot generate—was well-supported by biomarker data showing increased T-cell clonality in the combination arm.

The clinical signal is compelling, but panelists were candid about the distance between the data and widespread implementation. Personalized mRNA vaccines are, by definition, individualized—and the logistical demands of manufacturing, sequencing, and delivering a patient-specific product sit far outside the operational infrastructure of most community oncology programs. For pharmacists in those settings, the near-term work is less about protocol development and more about staying ahead of a technology that is moving quickly toward broader use.

The rare skin cancers portion of the session covered neoadjuvant cemiplimab in both cutaneous squamous cell carcinoma (cSCC) and basal cell carcinoma (BCC). The RAMPART trial (____) showed event-free and overall survival at 24 months both exceeding 80% in unresectable cSCC, while the BCC trial demonstrated a 60% objective response rate and disease control exceeding 90% in locally advanced head and neck disease, with meaningful organ preservation at anatomically sensitive sites. Small sample sizes and limited biomarker data temper both readouts—but the direction of the evidence supports continued investigation, and pharmacists should be building familiarity with these regimens ahead of broader adoption.

From Podium to Practice: Supportive Care and GLP-1’s

The supportive care session brought a different kind of precision into focus—not molecular, but patient-centered. Four abstracts together made the case for individualized, pharmacist-led management of the symptoms and comorbidities that shape how patients experience cancer treatment.

The bupropion XL data for cancer-related fatigue generated considerable discussion. The phase 3 trial showed a statistically significant improvement on the FACIT-Fatigue subscale compared with placebo, but the effect size was modest, and the placebo group also improved meaningfully. Biological sex was a significant predictor of benefit—women gained a clinically relevant improvement while men trended in the opposite direction—and ever-smokers appeared to derive more benefit than never-smokers, consistent with bupropion's dopaminergic mechanism.

The takeaway is not a blanket recommendation but a framework for patient-specific counseling around who is most likely to benefit and what realistic expectations look like. The frailty index analysis grounded the session in a reality oncology pharmacists encounter daily: across both hematologic and solid tumor populations, frailty was associated with significantly higher rates of toxicity and mortality with novel therapies, with risk compounding with each additional frailty point.

A retrospective analysis of GLP-1 receptor agonist uses across 6 solid tumor types closed the session on a thought-provoking note, with an overall survival signal observed in GLP-1 users compared to matched nonusers across multiple cancer types. The mechanism is unclear and the retrospective design limits causal conclusions—but the finding reflects growing interest in the intersection of metabolic health and tumor biology, and pharmacists at the interface of oncology and primary care are well-positioned to follow this literature as it develops.

Precision Medicine: From Report to Recommendation

Precision oncology has matured well beyond identifying mutations—the harder work now is building the clinical infrastructure to act on them consistently and correctly. The breakout session addressed that challenge directly, surveying the next-generation sequencing (NGS) landscape across hematologic and solid tumor malignancies, covering resistance mechanisms, ctDNA limitations, and the persistent gap between biomarker identification and actionable treatment.

Advancing Precision and Optimizing Outcomes in Thoracic Malignancies

Thoracic oncology closed the meeting on a note that captured the full complexity of where the field stands—simultaneously celebrating durable, practice-defining efficacy data while grappling with the limits of treatment intensification. The 7-year CROWN trial (NCT03052608) readout for lorlatinib in ALK-positive non-small cell lung cancer (NSCLC) was perhaps the most striking data point of the day: median progression-free survival still not reached, intracranial control that remains exceptional, and long-term benefit preserved even through dose reductions.

For pharmacists, dose modification is not a clinical compromise but a sustainable strategy backed by years of outcome data. Similarly, the LIBRETTO-432 trial (NCT04819100) reinforced that targeted therapy in early-stage disease is no longer a horizon—it is here, and it depends entirely on whether comprehensive biomarker testing is happening at diagnosis regardless of stage.

At the same time, the data from the concurrent thoracic radiation trial in extensive-stage SCLC served as a necessary counterweight. Adding radiation to chemoimmunotherapy produced more harm without survival benefit in a population that could least afford it—and that outcome deserves as much attention as the positive readouts. The arrival of ivonescimab, a bispecific antibody co-targeting PD-1 and VEGF, added a genuinely novel mechanism to a crowded first-line space in squamous NSCLC, and one that pharmacists should begin tracking closely.

A Meeting in Full

Across 2 days and a breadth of disease states—from GI oncology and breast cancer to melanoma, thoracic malignancies, and everything in between. The science is accelerating. Mechanisms are becoming more complex. Biomarker-driven therapy selection, frailty-informed dose management, individualized toxicity counseling, and the operational infrastructure required to support all of it are no longer aspirational—they are the baseline expectation of what excellent oncology pharmacy practice looks like.

The question the meeting left its attendees with was not whether pharmacists are capable of meeting that standard. The data, the case examples, and the conversations across both days made clear that they are. The question is whether the systems, the staffing, and the institutional support exist to let them.